Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: An open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study

Grob, Jean Jacques; Jouary, Thomas; Dreno, Brigitte; Asselineau, Julien; Gutzmer, Ralf; Hauschild, Axel; Leccia, Marie Therese; Landthaler, Michael; Garbe, Claus; Sassolas, Bruno; Herbst, Rudolf A.; Guillot, Bernard; Chene, Genevieve; Pehamberger, Hubert

Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: An open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study

Autor(en):

Grob, Jean Jacques; Jouary, Thomas; Dreno, Brigitte; Asselineau, Julien; Gutzmer, Ralf; Hauschild, Axel; Leccia, Marie Therese; Landthaler, Michael; Garbe, Claus; Sassolas, Bruno; Herbst, Rudolf A.; Guillot, Bernard; Chene, Genevieve; Pehamberger, Hubert

Tübinger Autor(en):

Garbe, Claus

Erschienen in:

European Journal of Cancer (2013), Bd. 49, H. 1, S. 166-174

Verlagsangabe:

Elsevier Sci Ltd

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1016/j.ejca.2012.07.018

ISSN:

0959-8049